%0 Case Reports
%T [Type 1 primary hyperoxaluria: From childhood to adult, how to manage adequately medical therapy compliance?]
%A Leflot M
%A Krzesinski JM
%A Collard L
%A Thomas A
%A Ghuysen MS
%J Nephrol Ther
%V 14
%N 3
%D May 2018
%M 29198962
%F 0.5
%R 10.1016/j.nephro.2017.06.004
%X We report the cases of three young patients suffering from type 1 primary hyperoxaluria, a metabolic genetic disorder characterized by intracellular accumulation of oxalate and which may result in end-stage renal disease with systemic impairment. A number of effective conservative therapeutic means are available for early management of affected children particularly when he is growing older. Despite the demonstrated efficacy of conservative therapy, compliance represents a major and daily challenge. Monitoring therapeutic compliance is thus an important task for physicians in charge of this disease. A better understanding of non-compliance causes is required to improve the follow-up of patients for whom treatment education must be a priority.